Infectious Disease

**LIAISON® Mumps IgG**

### Key Assay Features

- **Number of tests**: 100
- **Method**: Indirect Quantitative
- **Assay range**: 5 – 300 AU / mL
- **Solid Phase**: Recombinant nucleoprotein expressed in *P. pastoris*
- **Conjugate**: MoAb to human IgG conjugated to isoluminol derivative
- **Label**: ABEI
- **Sample**: 20 µL serum or plasma
- **Integral on board stability**: 8 weeks
- **Calibrators availability**: On board – positive and negative
- **Calibration stability**: 4 weeks
- **Controls availability**: Positive and negative (60 tests per control kit – code 318841)
- **Controls stability once opened**: 8 weeks

### Performance Characteristics

- **Cross-reactions**: Zero cross reactions observed with a panel consisting of antibodies to hCMV, EBV, rubella virus, parvovirus B19, measles, Toxoplasma, HSV, VZV, HAV, Treponema, ANA
- **Repeatability Coefficient of Variation**: 3.9 - 7.2 %
- **Reproducibility Coefficient of Variation (inter-site)**: 10.7 – 14.5 %

Diagnostic performance was assessed by testing 519 unselected specimens collected from a European laboratory routine (300 unselected individuals, 50 children ages 0-8 years, 130 subjects with serology suggestive of susceptibility to infection, 39 patients with serology suggestive of acute infection) against a commercially available reference EIA.

- **Diagnostic specificity**: 98.2% (164/167) (95% confidence interval: 94.8-99.6%)
- **Diagnostic sensitivity**: 98.5% (330/335) (95% confidence interval: 96.5-99.5%)

### Ordering Information

<table>
<thead>
<tr>
<th>Test Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>318840</td>
<td>LIAISON® Mumps IgG</td>
</tr>
<tr>
<td>318841</td>
<td>LIAISON® Control Mumps IgG</td>
</tr>
<tr>
<td>318830</td>
<td>LIAISON® Mumps IgM</td>
</tr>
<tr>
<td>318831</td>
<td>LIAISON® Control Mumps IgM</td>
</tr>
</tbody>
</table>

**AVAILABLE ON LIAISON® SYSTEMS**

Product availability subject to required regulatory approval